Factorsβ95% CIP-value TRECs 1 mMA0.224(0.034– 0.592)0.028* Younger donor age (BM)0.356(0.191– 1.150)0.007* 3 mYounger recipient age0.243(0.046– 0.781)0.028*

Slides:

Advertisements

Similar presentations

HEART TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):

Advertisements

A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.

UNRELATED DONOR TRANSPLANTS A Bacigalupo, Ospedale San Martino, Genova, Italy.

Slide 1Fig. 11.1, p.337. Slide 2Fig. 11.2, p.338.

Slide 1Fig. 19.1, p Slide 2Fig. 19.2, p. 583.

Slide 1Fig. 21.1, p.641. Slide 2Fig. 21.2, p.642.

Slide 1Fig. 10.1, p.293. Slide 2Fig. 10.1a, p.293.

Slide 1Fig. 5.1, p.113. Slide 2Fig. 5.1a, p.113 Slide 3Fig. 5.1b, p.113.

Fig. 3-1, p. 67. Fig. 3-2, p. 67 Fig. 3-3, p. 68.

P Fig. 6-1, p. 193 Fig. 6-2, p. 193 Fig. 6-3, p. 195.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

1 times table 2 times table 3 times table 4 times table 5 times table

Supplementary Table 1. Impact of pretransplant factors on the incidence of pulmonary complications FactorUnivariate RR (95% CI)P-valueMultivariate RR *1.

G. S / AIH 2006 Graft-versus-Host disease Physiopathology Gérard Socié, MD PhD Hospital Saint Louis Translating experimental into clinical knowledge.

Differences between Genders And Age groups. Hypothesis: Male students believe they perform better in traditional classes over online classes while female.

Upfront Transplant Strategies in Aplastic Anemia

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Tables Learning Support

基督再來（一）. 經文： 1 你們心裡不要憂愁；你們信神，也當信我。 2 在我父的家裡有許多住處；若是沒有，我就早已告訴你們了。我去原是為你們預備地去。 3 我若去為你們預備了地方，就必再來接你們到我那裡去，我在那裡，叫你們也在那裡， ] ( 約 14 ： 1-3)

Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.

Table S1: Antibodies Used for Flow Cytometric Analysis

Retrospective analysis of conditioning regimen containing decitabine of allogeneic stem cell transplantation for myelodysplastic syndrome and myeloproliterative.

Supplemental table 1 Patients' characteristics Variables Number

PB 26 GRAPHICS.

Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular.

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.

Ematologia, Ospedali Riuniti, Bergamo

Слайд-дәріс Қарағанды мемлекеттік техникалық университеті

Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan.

High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.

.. -"""--..J '. / /I/I =---=-- -, _ --, _ = :;:.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

II //II // \ Others Q.

Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children Matthias Eyrich, Gernot.

I1I1 a 1·1,.,.,,I.,,I · I 1··n I J,-·

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Supplementary Table VI

Relating Autoimmune Cytopenias after Hematopoietic Cell Transplantation (HCT) to Transplant-Variables and Immune Reconstitution: A Predictor Analysis

A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van.

Higher CD34+ and CD3+ Cell Doses in the Graft Promote Long-Term Survival, and Have No Impact on the Incidence of Severe Acute or Chronic Graft-versus-Host.

Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Employees (thousands)

Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,

Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

3 times tables.

6 times tables.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors by Manabu Wakamatsu, Seitaro Terakura,

Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal:

Clinical Lymphoma, Myeloma and Leukemia

Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation:

Supplementary Table IV

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.

. '. '. I;.,, - - "!' - -·-·,Ii '.....,,......, -,

Frédéric Baron, Rainer Storb

Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity.

Biology of Blood and Marrow Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia/Lymphoma: Impact of Antithymocyte Globulin.

Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation H Khoury, K Trinkaus, M.J Zhang, D Adkins,

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Factorsβ95% CIP-value TRECs 1 mMA0.224(0.034– 0.592)0.028* Younger donor age (BM)0.356(0.191– 1.150)0.007* 3 mYounger recipient age0.243(0.046– 0.781)0.028* Younger donor age (BM)0.555(0.623– 1.689)0.000* Relation0.222(0.007– 0.710)0.045* 6 mYounger recipient age0.342(0.277– 1.595)0.006* No chronic GVHD0.498(0.714–1.880)0.000* 1 yYounger recipient age0.584(0.922– 2.301)0.000* PID0.366(0.221– 1.809)0.013* Younger donor age (BM)0.532(0.504–3.417)0.011* BM (compared with CB)-0.356(-1.865– )0.023† No chronic GVHD0.467(0.527– 2.041)0.001* 2 yYounger recipient age0.707(0.974– 2.592)0.000* PID0.584(0.567– 2.500)0.003* sjKRECs 1 mYounger donor age (BM)0.396(0.187– 0.833)0.003* BM (compared with CB)-0.252(-0.772– )0.018† 3 mYounger recipient age0.233(0.048– 1.287)0.035* Younger donor age (BM)0.425(0.445– 2.132)0.004* BM (compared with CB)-0.272(-1.325– 0.117)0.020† Grade 0–2 aGVHD0.370(0.485–1.984)0.002* No chronic GVHD0.392(0.478–1.538)0.000* No use of PSL/HDC0.309(0.246– 1.334)0.005* 6 mYounger recipient age0.423(0.522– 1.794)0.001* MA0.316(0.192– 1.466)0.012* Younger donor age (BM)0.448(0.257–2.369)0.017* Grade 0–2 aGVHD0.320(0.209– 2.065)0.017* No chronic GVHD0.281(0.085– 1.378)0.027* No use of ATG0.339(0.285– 1.730)0.007* 1 yYounger recipient age0.492(0.462– 1.567)0.001* PID0.329(0.080– 1.277)0.027* PB (compared with CB)-0.469(-2.884– )0.037† Grade 0–2 aGVHD0.436(0.396– 2.220)0.006* No chronic GVHD0.501(0.477– 1.587)0.001* 2 yYounger recipient age0.632(0.475– 1.669)0.001* PID0.459(0.099–1.523)0.028* Younger donor age (BM)0.761(0.493– 2.266)0.007* BM (compared with CB)-0.593(-1.381– )0.005† PB (compared with CB)-0.701(-3.087– )0.016† Grade 0–2 aGVHD0.682(0.701–2.544)0.002* No chronic GVHD0.447(0.070– 1.447)0.032* Supplementary Table II. Univariate analysis of factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs. *Significant favorable factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs. †Significant unfavorable factors that contributed to the levels of TRECs, sjKRECs, and cjKRECs. Factorsβ95% CIP-value cjKRECs 1 mYounger donor age (BM)0.353(0.190– 1.185)0.008* 3 mYounger recipient age0.224(0.023– 1.405)0.043* MA0.239(0.063– 1.338)0.032* Younger donor age (BM)0.525(0.936– 2.793)0.000* BM (compared with CB)-0.326(-1.672– )0.005† Grade 0–2 aGVHD0.310(0.301– 2.023)0.009* No chronic GVHD0.392(0.532– 1.714)0.000* No use of PSL/HDC0.297(0.235– 1.447)0.007* 6 mYounger recipient age0.451(0.673– 2.058)0.000* MA0.252(0.012– 1.449)0.046* Younger donor age (BM)0.422(0.191– 2.657)0.025* PB (compared with CB)-0.438(-2.473– )0.012† Grade 0-2 of aGVHD0.267(0.004– 2.091)0.049* No chronic GVHD0.332(0.256– 1.658)0.008* No use of ATG0.295(0.158– 1.779)0.020* 1 yYounger recipient age0.459(0.414– 1.630)0.002* Younger donor age (BM)0.466(0.101– 1.647)0.029* BM (compared with PB)0.377(0.033–2.091)0.044* Grade 0–2 aGVHD0.414(0.358– 2.429)0.010* No chronic GVHD0.358(0.149– 1.447)0.017* 2 yPID0.505(0.171– 1.352)0.014* BM (compared with CB)-0.478(-0.790– )0.028† PB (compared with CB)-0.722(-3.091– )0.012† BM (compared with PB)0.620(0.280–2.470)0.018* Grade 0–2 aGVHD0.659(0.551– 2.236)0.003* No chronic GVHD0.493(0.143– 1.287)0.017*